Payment & Shipping Terms:
Orlistat (CAS NO.96829-58-2) is a drug designed to treat obesity. It is mainly used for preventing the absorption of fats from the human diet, thereby reducing caloric intake. Besides, it is intended for use in conjunction with a physician-supervised reduced-calorie diet.
Molecular Formula: C29H53NO5
3. Analysis of the standard for 99%
|Appearance||while to off-while powder||White powder|
|Identification||HPLC retention time||Conforms|
|Melting Point||42 ºC -45°C||42°C-44°C|
|Specific optical rotation||-31.0°~-41.0°||-36.0°|
|Purity by HPLC||no less than 98.0%||98.5%|
|Total impurity||no more than 2.0%||1.6%|
|Max Individual impurity||no more than 0.5%||0.3%|
|Water content%(K&F)||no more than 0.5%||0.1%|
|Residual solvents||EtOH no more than 0.5%||N.D|
|EtAC no more than 0.5%||N.D|
|n-Heptane no more than 0.5%||less than 0.1%|
|Residue on ignition||less than 0.2%||0.10%|
|Heavy metals as Pb||no more than 20ppm||less than20ppm|
|Assay (HPLC)||no less than 98.0%||98.60%|
|Conclusion||Meets the Requirements|
Orlistat is used for the treatment of obesity.The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass.After orlistat was stopped, a significant number of subjects regained weight—up to 35% of the weight they had lost.
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
Contact Person: admin